Evidence map›Paper›PMID 37063117›Full record

ArticleJTCVS open2023

The majority of patients with resectable incidental lung cancers are ineligible for lung cancer screening.

Nanruoyi Zhou, John Deng, Claire Faltermeier, Terrance Peng, Hanna Mandl, Sha'shonda Revels, Paul Toste, Robert B Cameron, Jay M Lee, Jane Yanagawa

Open access · goldAbstract read
In one paragraph

Article in JTCVS open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Observational
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Nanruoyi ZhouSurgery, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, NY.
John DengDavid Geffen School of Medicine at University of California, Los Angeles, Los Angeles, Calif.
Claire FaltermeierSurgery, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, Calif.
Terrance PengSurgery, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, Calif.
Hanna MandlDavid Geffen School of Medicine at University of California, Los Angeles, Los Angeles, Calif.
Sha'shonda RevelsDivision of Thoracic Surgery, University of California, Los Angeles, Los Angeles, Calif.
Paul TosteDivision of Thoracic Surgery, University of California, Los Angeles, Los Angeles, Calif.
Robert B CameronDivision of Thoracic Surgery, University of California, Los Angeles, Los Angeles, Calif.
Jay M LeeDivision of Thoracic Surgery, University of California, Los Angeles, Los Angeles, Calif.
Jane YanagawaDivision of Thoracic Surgery, University of California, Los Angeles, Los Angeles, Calif.
University of California, Los Angeles · USNewYork–Presbyterian Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The study objective was to determine what proportion of asymptomatic patients had resectable lung cancer detected through lung cancer screening versus incidentally. Methods: We performed a retrospective study of patients who underwent resection for lung cancer between January 2015 and December 2020. We then assessed whether asymptomatic patients with incidentally found lung cancers were eligible for lung cancer screening using the National Comprehensive Cancer Network, United States Preventive Services Task Force, Centers for Medicare & Medicaid Services, American College of Chest Physicians, American Cancer Society, and American Society of Clinical Oncology guidelines. Results: Of 539 patients who underwent resection for primary lung cancer, 437 (81%) were asymptomatic and 355 (66%) of these patients had lung cancer found discovered incidentally. Of the 355 patients with incidentally detected lung cancer, 10 were excluded for insufficient data. Of the remaining 345 patients, 110 (32%) would have been eligible for screening using National Comprehensive Cancer Network guidelines, 65 (19%) using 2021 United States Preventive Services Task Force guidelines, 53 (15%) using 2013 United States Preventive Services Task Force guidelines, 64 (19%) using 2022 Centers for Medicare & Medicaid Services guidelines, 52 (15%) using 2015 Centers for Medicare & Medicaid Services/American College of Chest Physicians guidelines, and 45 (13%) using American Cancer Society/American Society of Clinical Oncology guidelines. Of the 280 patients who were screen ineligible by 2021 United States Preventive Services Task Force criteria, 143 patients (51%) never smoked, 112 patients (40%) quit smoking more than 15 years ago, 89 patients (32%) did not smoke at least 20 pack-years, and 44 patients (16%) were ineligible due to age. Conclusions: The majority of asymptomatic patients with resectable lung cancers had lung cancer identified incidentally and not through lung cancer screening. Most of these patients were not eligible for screening under current guidelines. This study suggests a need for improved lung cancer screening implementation and further investigation in the identification and assessment of risk factors for lung cancer.

Indexed as

guidelineslung cancerscreening

Identifiers

PMID37063117
PMCPMC10091284
OpenAlexW4311754161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.